お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
966754

軸性脊椎関節炎 (axSpA):疫学的予測 (2030年まで)

Axial Spondyloarthritis (axSpA) - Epidemiology Insight - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.13円
軸性脊椎関節炎 (axSpA):疫学的予測 (2030年まで)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要国 - 米国、欧州主要5ヶ国 (EU5:フランス・ドイツ・イタリア・スペイン・英国) 、日本 - におけ軸性脊椎関節炎 (axSpA) の疫学的動向と今後の見通しについて分析しております。

目次

第1章 主な考察

第2章 軸性脊椎関節炎 (axSpA):エグゼクティブサマリー

第3章 軸性脊椎関節炎 (axSpA):疾患概要

  • イントロダクション
  • 兆候と症状
  • 病態生理
  • 危険因子
  • 診断基準

第5章 軸性脊椎関節炎 (axSpA) の疫学と患者人口

  • 疫学分析のポイント
  • 仮定と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 軸性脊椎関節炎 (axSpA):主要7ヶ国における疫学シナリオ (2017年~2030年)
  • 米国の疫学的動向
    • 米国国内の軸性脊椎関節炎 (axSpA) の疫学シナリオ (2017年~2030年)
  • 欧州5ヶ国:国別の疫学的動向
    • ドイツの疫学的動向
    • フランスの疫学的動向
    • イタリアの疫学的動向
    • スペインの疫学的動向
    • 英国の疫学的動向
  • 日本の疫学的動向
    • 日本国内の軸性脊椎関節炎 (axSpA) の疫学シナリオ (2017年~2030年)

第6章 治療アルゴリズム、現在の治療・診療方法

  • 軸性脊椎関節炎 (axSpA) の治療・管理方法
  • 軸性脊椎関節炎 (axSpA) の治療アルゴリズム

第7章 業界の有識者 (KOL) の見解

第8章 アンメットニーズ

第9章 付録

第10章:DelveInsightのサービス内容

第11章 免責事項

第12章:DelveInsightについて

図表

List of Tables

  • Table 1: Axial Spondyloarthritis (axSpA) Epidemiology in 7MM (2017-2030)
  • Table 2: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Axial Spondyloarthritis (axSpA) Epidemiology in the United States (2017-2030)
  • Table 4: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Axial Spondyloarthritis (axSpA) Epidemiology in Germany (2017-2030)
  • Table 6: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Axial Spondyloarthritis (axSpA) Epidemiology in France (2017-2030)
  • Table 8: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Axial Spondyloarthritis (axSpA) Epidemiology in Italy (2017-2030)
  • Table 10: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Axial Spondyloarthritis (axSpA) Epidemiology in Spain (2017-2030)
  • Table 12: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Axial Spondyloarthritis (axSpA) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Axial Spondyloarthritis (axSpA) Epidemiology in Japan (2017-2030)
  • Table 16: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Axial Spondyloarthritis (axSpA) Epidemiology in 7MM (2017-2030)
  • Figure 2: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Axial Spondyloarthritis (axSpA) Epidemiology in the United States (2017-2030)
  • Figure 4: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Axial Spondyloarthritis (axSpA) Epidemiology in Germany (2017-2030)
  • Figure 6: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Axial Spondyloarthritis (axSpA) Epidemiology in France (2017-2030)
  • Figure 8: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Axial Spondyloarthritis (axSpA) Epidemiology in Italy (2017-2030)
  • Figure 10: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Axial Spondyloarthritis (axSpA) Epidemiology in Spain (2017-2030)
  • Figure 12: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Axial Spondyloarthritis (axSpA) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Axial Spondyloarthritis (axSpA) Epidemiology in Japan (2017-2030)
  • Figure 16: Axial Spondyloarthritis (axSpA) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1029

DelveInsight's 'Axial Spondyloarthritis (axSpA) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Axial Spondyloarthritis (axSpA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Axial Spondyloarthritis (axSpA) Understanding

The DelveInsight Axial Spondyloarthritis (axSpA) epidemiology report gives a thorough understanding of the Axial Spondyloarthritis (axSpA) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Axial Spondyloarthritis (axSpA) in the US, Europe, and Japan. The report covers the detailed information of the Axial Spondyloarthritis (axSpA) epidemiology scenario in seven major countries (US, EU5, and Japan).

Axial Spondyloarthritis (axSpA) Epidemiology Perspective by DelveInsight

The Axial Spondyloarthritis (axSpA) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Axial Spondyloarthritis (axSpA) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Axial Spondyloarthritis (axSpA) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Axial Spondyloarthritis (axSpA) Detailed Epidemiology Segmentation

The Axial Spondyloarthritis (axSpA) epidemiology covered in the report provides historical as well as forecasted Axial Spondyloarthritis (axSpA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Axial Spondyloarthritis (axSpA) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Axial Spondyloarthritis (axSpA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Axial Spondyloarthritis (axSpA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Axial Spondyloarthritis (axSpA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Axial Spondyloarthritis (axSpA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Axial Spondyloarthritis (axSpA)
  • The report provides the segmentation of the Axial Spondyloarthritis (axSpA) epidemiology

Report Highlights:

  • 11-Year Forecast of Axial Spondyloarthritis (axSpA) epidemiology
  • 7MM Coverage
  • Total Cases of Axial Spondyloarthritis (axSpA)
  • Total Cases of Axial Spondyloarthritis (axSpA) according to segmentation
  • Diagnosed cases of Axial Spondyloarthritis (axSpA)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Axial Spondyloarthritis (axSpA) ?
  • What are the key findings pertaining to the Axial Spondyloarthritis (axSpA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Axial Spondyloarthritis (axSpA) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Axial Spondyloarthritis (axSpA) ?
  • What are the currently available treatments of Axial Spondyloarthritis (axSpA) ?

Reasons to buy:

  • The Axial Spondyloarthritis (axSpA) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Axial Spondyloarthritis (axSpA) market
  • Quantify patient populations in the global Axial Spondyloarthritis (axSpA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Axial Spondyloarthritis (axSpA) therapeutics in each of the markets covered
  • Understand the magnitude of Axial Spondyloarthritis (axSpA) population by its epidemiology
  • The Axial Spondyloarthritis (axSpA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Axial Spondyloarthritis (axSpA)

3. Axial Spondyloarthritis (axSpA) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Axial Spondyloarthritis (axSpA) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Axial Spondyloarthritis (axSpA) Treatment and Management
  • 6.2. Axial Spondyloarthritis (axSpA) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.